Interview with Byoung Joo Gwag, CEO, President, Neurotech Pharmaceuticals
What was the vision behind the creation of Neurotech back in 1998, originally as a Research Center, and then as an independent bio-tech company? It all began in 1998 when…
Address: 4F Hyunwoo Building, Gomae- dong 381-1, Giheung-gu, Yongin -si, Gyeonggi-do446-901, Republic of Korea
Tel: 82-31-215-9985
Web: http://gntpharma.com/intro/
Established in 1998 Neurotech Pharmaceuticalshas received the G7 Project Award from the Ministry of Science & Technology:Development of Alzheimer’s Disease models and Neuroprotectant compounds.Neurotech team members are working diligently with shareholder support to develop the next generation of medicines.Neurotech has been developing Neu2000 and AAD-2004 over the last 8 years and has recently discovered two additional promising compounds. Neurotech has also expanded its drug development capabilities over this period. In preparing for competition in the global marketplace, Neurotech has secured sufficient cash flow for R&D Funding through public listing, employing a conservative business model, and establishing a new drug development infrastructure through the introduction of IT. Its partner, Eolith, is a company that specializes in Broadband Convergence Network technology. Neurotech is working with Eolith and large medical center to construct a Ubiquitous Health Monitoring System (UHMS) to select patients with stroke and Alzheimer’s and maximize the efficacy of drugs. Neurotech ultimately seeks to gain entry into the pharmaceutical industry through clinical studies and the marketing of new drugs.In 2008, Neurotech has successfully completed the Neu2000 clinical phase I study in the U.S.
What was the vision behind the creation of Neurotech back in 1998, originally as a Research Center, and then as an independent bio-tech company? It all began in 1998 when…
Examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. Here, Eugene Kim, Seoul office leader of executive…
Rana Azfar, vice-president & general manager of Novo Nordisk Korea offers his impressions of the Korean market since moving from Pakistan. Azfar discusses how the most innovative insulin products have…
Young-Woo Park, CEO of Y-Biologics – renowned for their library with diversity of 1011 – unveils their plan to be the first in Korea to develop the PD-1 antibody as…
Yong Zu Kim, founder and CEO of Lego Chem, discusses his company’s two areas of focus, anti-infectives and antibody drug conjugates. Dr Kim explains how his strategy has changed from…
Kyoung-June Lee, CEO of JW CreaGene, lifts the lid on their novel technology of developing an immuno-oncology treatment from dendritic cells, which act as a command centre of the immune…
Dr BG Rhee, CEO of SCM Lifescience discusses their patented proprietary subfraction technology to extract high purity cell cultures, and the impact this will have on the efficacy, cell differentiation…
Professor Jong In Lim, cyber security specialist and president of the Institute for Cyber Security and Privacy (ICSP) provides his assessment of the current situation for information security in Korea,…
Deborah Chee, President of KoNECT (Korea National Enterprise for Clinical Trials), discusses what it takes to build one of the world’s leading clinical trials ecosystems and highlights the importance of…
Hakhyun Nam, co-founder and CTO at i-SENS, Inc. a developer of glucose sensor devices, reveals his path to running a globally successful medical devices company, and how i-SENS overcame early…
Julien Samson, vice president and general manager of GSK Korea explains how GSK’s new global strategy is being delivered within the Korean affiliate. Mr Samson explains the focus areas for…
As the 3rd largest pharma region in Asia, Korea’s booming pharma industry owes much to its mass of family-run conglomerates known as Chaebol. It comes as no surprise to find tech…
Shingyu Bae, CEO of MDimune, explains how the company’s new exosome drug delivery system increases efficacy and reduces toxicity compared with other oncology products. He also discusses the potential and…
See our Cookie Privacy Policy Here
